RESUMO
Laryngotracheo-esophageal cleft is a rare congenital anomaly that results from complete or partial failure of the development of the tracheoesophageal septum. The presenting symptoms include stridor, respiratory distress, and coughing or cyanotic episodes with feeding. There are four classifications for laryngeal clefts; the severity depends on the type present. We discuss the anesthesia management of a neonate with a Type IV cleft who presented for an emergency gastric division to prevent pulmonary aspiration and later returned for final repair of the defect.
Assuntos
Anestesia/métodos , Esôfago/anormalidades , Laringe/anormalidades , Anestésicos Inalatórios/administração & dosagem , Anestésicos Intravenosos/administração & dosagem , Ponte Cardiopulmonar/métodos , Esôfago/cirurgia , Feminino , Gastrostomia/métodos , Humanos , Recém-Nascido , Intubação Intratraqueal/métodos , Isoflurano/administração & dosagem , Laringe/cirurgia , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Pancurônio/administração & dosagem , Piperidinas/administração & dosagem , Pneumonia Aspirativa/complicações , Doenças Raras , Remifentanil , Índice de Gravidade de Doença , Traqueostomia , Resultado do Tratamento , Brometo de Vecurônio/administração & dosagemRESUMO
AIM: Remifentanil hydrochloride is an ultra-short acting m-opioid receptor agonist. This study compared the use of remifentanil with that of fentanyl during elective supratentorial craniotomy in a target controlled infusion (TCI)-propofol anesthesia regimen and evaluated the quality of recovery from anesthesia. METHODS: After written informed consent for this prospective study, 40 adult patients were randomly divided into 2 groups: in group F analgesia was provided with fentanyl 2-3 mg kg(-1) h(-1) and in group R with remifentanil 0.25 mg kg(-1) h(-1). Anesthesia was induced with thiopental and pancuronium bromide, and maintained with propofol-TCI, pancuronium, air and oxygen and fentanyl (group F) or remifentanil (group R), respectively. After tracheal intubation, infusion rate of remifentanil was reduced and then adjusted to maintain stable hemodynamics. Hemodynamics and recovery time were monitored for 60 min after surgery. Analgesic requirements, propofol intraoperative consumption, nausea and vomiting in postoperative period were monitored. Recovery was evaluated according to a modified Aldrete score. RESULTS: Baseline hemodynamics were similar in both groups. Mean arterial pressure differed between the 2 groups (P<0.05) with the greatest decrease in group R during dura opening (P<0.001). Postoperative mean arterial pressure was higher in group R. Patients in group R exhibited a faster recovery. The incidence of nausea and vomiting was similar in the 2 groups. Noteworthy, there was a reduction in the amount of propofol used in group R. CONCLUSIONS: Remifentanil appears to be a reasonable alternative to fentanyl during elective surgery of supratentorial lesions.
Assuntos
Anestesia Intravenosa , Anestésicos Intravenosos/administração & dosagem , Craniotomia , Fentanila/administração & dosagem , Piperidinas/administração & dosagem , Propofol/administração & dosagem , Receptores Opioides mu/agonistas , Neoplasias Supratentoriais/cirurgia , Adulto , Idoso , Período de Recuperação da Anestesia , Anestésicos Intravenosos/efeitos adversos , Anestésicos Intravenosos/farmacologia , Delírio/induzido quimicamente , Procedimentos Cirúrgicos Eletivos , Feminino , Fentanila/farmacologia , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Pancurônio/administração & dosagem , Piperidinas/efeitos adversos , Piperidinas/farmacologia , Propofol/farmacologia , Estudos Prospectivos , Remifentanil , Tiopental/administração & dosagemRESUMO
The potential value of pretreatment urinary 3-methoxy, 4-hydroxyphenylethyleneglycol (MHPG) levels to predict the therapeutic response to antidepressants was studied by measuring urinary MHPG output in 42 depressed inpatients treated with a selective inhibitor of serotonin (Indalpine) or noradrenaline (Maprotiline) reuptake. Among the 42 depressed inpatients there were 33 cases of major depressive episode. Patients were treated for at least 3 weeks, firstly with intravenous infusions of maprotiline or indalpine which have been administered at random. No difference in pretreatment urinary MHPG levels was found between the responders to indalpine (1.08 +/- 0.48 micrograms/24 h/mg of creatinine) and the responders to maprotiline (1.15 +/- 0.62 micrograms/24 h/mg of creatinine). However, there was a difference in the pretreatment levels of urinary MHPG between the non-responders to indalpine (0.56 +/- 0.28 microgram/24 h/mg of creatinine) and the non-responders to maprotiline (1.37 +/- 0.68 micrograms/24 h/mg of creatinine). No correlation between this biochemical parameter and HDRS score was found. These results indicate that, in this study, there is no obvious relationship between the pretreatment urinary MHPG levels in depressed patients and their therapeutic response to specific inhibitors of noradrenaline or serotonin reuptake. However, there was a positive trend towards a lower pretreatment MHPG level to be associated with lack of response to indalpine.